Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation

Transplantation

Volumn 86, Issue 1, 2008, Pages 10-15

  Li, Xian Liang ^a,b,c   Ménoret, Séverine ^a,b,c   Le Mauff, Brigitte ^a,b,c   Angin, Mathieu ^a,b,c   Anegon, Ignacio ^a,b,c  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

CD154; CD40; CD8+ Treg; Costimulation; Tolerance; Transplantation

Indexed keywords

ANTIBODY; BELATACEPT; CALCINEURIN INHIBITOR; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD45RB ANTIBODY; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 ANTIBODY; RAPAMYCIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ALLOTRANSPLANTATION; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOEMBOLISM; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; ORGAN TRANSPLANTATION; REVIEW; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CD40 LIGAND; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TRANSPLANTATION TOLERANCE;

EID: 49849101512     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817c4b97     Document Type: Short Survey

References (82)

1. Zhai Y, Kupiec-Weglinski JW. The CD154-CD40 costimulation pathway in organ transplantation. Transplant Reviews 2004; 18: 10.
2. Munroe ME, Bishop GA. A costimulatory function for T cell CD40. J Immunol 2007; 178: 671.
3. + T cell memory. Science 2002; 297: 2060.
4. Van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997; 9: 330.
5. Lesley R, Kelly LM, Xu Y, et al. Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival. Proc Natl Acad Sci USA 2006; 103: 10717.
6. + T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000; 164: 512.
7. Blair PJ, Riley JL, Harlan DM, et al. CD40 ligand (CD154) triggers a short-term CD4( + ) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000; 191: 651.
8. Monk NJ, Hargreaves RE, Marsh JE, et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003; 9: 1275.
9. Quezada SA, Bennett K, Blazar BR, et al. Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: The interplay of clonal anergy and immune regulation. J Immunol 2005; 175: 771.
10. + alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: Implications for anti-CD154 immunotherapy. J Immunol 2002; 169:5401.
11. + regulatory T cells. Transplantation 2005; 79: 147.
12. + T regulatory cell induction and function in transplant recipients after CD154 blockade is TLR4 independent. J Immunol 2006; 176: 5988.
13. Masunaga T, Yamashita K, Sakihama H, et al. Dimeric but not mono-meric soluble CD40 prolongs allograft survival and generates regulatory T cells that inhibit CTL function. Transplantation 2005; 80: 1614.
14. low T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 1096.
15. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442: 997.
16. Guillot C, Guillonneau C, Mathieu P. et al. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsive-ness, but does not prevent chronic rejection. J Immunol 2002; 168: 1600.
17. Markees TG, Phillips NE, Gordon EJ, et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4( +) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101: 2446.
18. Yamashita K, Ollinger R, McDaid J, et al. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. Faseb J 2006; 20: 776.
19. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
20. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
21. Borrow P, Tough DF, Eto D, et al. CD40 ligand-mediated interactions are involved in the generation of memory CD8( + ) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J Virol 1998; 72: 7440.
22. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
23. Kirk AD, BurklyLC, Batty DS, etal. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
24. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003; 75: 637.
25. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174: 542.
26. Tsai MK, Ho HN, Chien HF, et al. The role of B7 ligands (CD80 and CD86) in CD152-mediated allograft tolerance: A crosscheck hypothesis. Transplantation 2004; 77: 48.
27. +-medi-ated responses under costimulation blockade. J Immunol 2006; 176: 5240.
28. Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med 1998; 188: 205.
29. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097.
30. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102: 564.
31. Guillonneau C, Seveno C, DugastAS, etal. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007; 179: 8164.
32. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
33. Hancock WW, Sayegh MH, Zheng XG, et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996; 93:13967.
34. Guillonneau C, Louvet C, Renaudin K, et al. The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. J Immunol 2004; 172: 1619.
35. Shirasugi N, Adams AB, Durham MM, et al. Prevention of chronic rejection in murine cardiac allografts: A comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002; 169: 2677.
36. Exner BG, Acholonu IN, Bergheim M, et al. Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts. Acta Hematol 1999; 101: 78.
37. Guillonneau C, Aubry V, Renaudin K, et al. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade. Transplantation 2005; 80:255.
38. Fuleihan R, Ramesh N, Horner A, et al. Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J Clin Invest 1994; 93: 1315.
39. Li Y, LiXC, Zheng XX, etal. Blocking both signal 1 and signal 2 ofT-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298.
40. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6 (5 Pt 1): 876.
41. Bartlett AS, McCall JL, Ameratunga R, et al. Intragraft gene and protein expression in rat liver allografts treated with costimulatory blockade alone or in combination with CyA. J SurgRes 2003; 115: 1.
42. Haanstra KG, Sick EA, Ringers J, et al. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation 2005; 79: 1623.
43. Koenen HJ, Fasse E, Joosten I. Cyclosporine preserves the anergic state of human T cells induced by costimulation blockade in vitro. Transplantation 2005; 80: 522.
44. Preston EH, Xu H, Dhanireddy KK, et al. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant 2005; 5: 1032.
45. Metzler B, Gfeller P, Bigaud M, et al. Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection. J Immunol 2004; 173: 7025.
46. Zhang Q, Fairchild RL, Reich MB, et al. Inhibition of Src kinases combined with CD40 ligand blockade prolongs murine cardiac allograft survival. Transplantation 2005; 80: 1112.
47. Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166: 322.
48. Wang Y, Dai H, Liu Z, et al. Neutralizing IL-7 promotes long-term allograft survival induced by CD40/CD40L costimulatory blockade. Am J Transplant 2006; 6: 2851.
49. Azimzadeh AM, Pfeiffer S, Wu G, et al. Alloimmunity in primate heart recipients with CD154 blockade: Evidence for alternative costimulation mechanisms. Transplantation 2006; 81: 255.
50. Haanstra KG, Sick EA, Ringers J, et al. No synergy between ATG induction and costimulation blockade induced kidney allograft survival in rhesus monkeys. Transplantation 2006; 82: 1194.
51. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13: 391.
52. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591.
53. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247.
54. Inwald DP, McDowall A, Peters MJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041.
55. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
56. Koyama I, Kawai T, Andrews D, et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004; 77: 460.
57. Xu H, Zhang X, Mannon RB, et al. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest 2006; 116:769.
58. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74:933.
59. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84: 1020.
60. Uno M ST, Aoyagi T. Immunosuppression by a novel anti-CD40 mAb, 4D11, is not abrogated by combined treatment with tacrolimus for renal transplantation in cynomolgus monkeys. Am J Transplant 2007; 7(Suppl): 202.
61. Kumanogoh A, Wang X, Lee I, et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: A role of CD40 in regulatory T cell development. J Immunol 2001; 166: 353.
62. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431.
63. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
64. + regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007; 17:243.
65. Gauchat JF, Aubry JP, Mazzei G, et al. Human CD40-ligand: Molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett 1993; 315: 259.
66. Castle BE, Kishimoto K, Stearns C, et al. Regulation of expression of the ligand for CD40 on T helper lymphocytes. J Immunol 1993; 151: 1777.
67. + T cells with dendritic cells. Eur J Immunol 1996; 26:3137.
68. + T cells and is quickly expressed on the cell surface in an antigen-specific manner. Blood 2007; 110:2520.
69. Matthies KM, Newman JL, Hodzic A, et al. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol 2006; 241: 47.
70. + T cell clones allow B cell growth and differentiation. Eur J Immunol 1995; 25: 2972.
71. Grammer AC, McFarland RD, Heaney J, et al. Expression, regulation, and function of B cell-expressed CD154 in germinal centers. J Immunol 1999; 163: 4150.
72. Grammer AC, Bergman MC, MiuraY,et al. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol 1995; 154: 4996.
73. McLellan AD, Sorg RV, Williams LA, et al. Human dendritic cells activate T lymphocytes via a CD40:CD40 ligand-dependent pathway. Eur J Immunol 1996; 26: 1204.
74. Pinchuk LM, Klaus SJ, Magaletti DM, et al. Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. J Immunol 1996; 157: 4363.
75. Karmann K, Hughes CC, Schechner J, et al. CD40 on human endothe-lial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995; 92: 4342.
76. Chai H, Yan S, Wang H, et al. CD40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells. Surgery 2006; 140: 236.
77. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931.
78. Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L) - Subcellular localization, regulationof expression, and inhibition by clopidogrel. Platelets 2001; 12: 74.
79. Prasad KS, AndreP, Yan Y,et al. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 2003; 10: 356.
80. Rehman KK, Bertera S, Trucco M, et al. Immunomodulation by adenoviral-mediated sCD40Ig gene therapy for mouse allogeneic islet transplantation. Transplantation 2007; 84: 301.
81. Nanji SA, Hancock WW, Luo B, et al. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes 2006; 55: 27.
82. Pearl JP, Xu H, Leopardi F, et al. CD154 blockade, sirolimus, and donor-specific transfusion prevents renal allograft rejection in cyno-molgus monkeys despite homeostatic T-cell activation. Transplantation 2007; 83: 1219.